SYRE

SEC source: 0001636282-25-000066 · wk-form4_1748896579.xml · derivative · entry 1

McKenna Mark C. · CIK 0001749623 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-05-29

F1 · derivative.exercise_date: This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0001636282-25-000065 · wk-form4_1748896522.xml · derivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-05-29

F1 · derivative.exercise_date: This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0001636282-25-000064 · wk-form4_1748896459.xml · derivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-05-29

F1 · derivative.exercise_date: This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0001636282-25-000009 · wk-form4_1737149753.xml · derivative · entry 1

Sloan Sheldon · CIK 0002038798 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,500

Underlying: Common Stock · 95,500 shares

Expires 2035-01-15

F1 · derivative.exercise_date: This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

SEC source: 0001636282-25-000010 · wk-form4_1737149801.xml · derivative · entry 1

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,500

Underlying: Common Stock · 95,500 shares

Expires 2035-01-15

F1 · derivative.exercise_date: This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

SEC source: 0001636282-25-000008 · wk-form4_1737149707.xml · derivative · entry 1

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 370,000

Underlying: Common Stock · 370,000 shares

Expires 2035-01-15

F1 · derivative.exercise_date: This option represents a right to purchase 370,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

SEC source: 0001636282-25-000007 · wk-form4_1737149638.xml · derivative · entry 1

King-Jones Heidy · CIK 0001794898 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,500

Underlying: Common Stock · 95,500 shares

Expires 2035-01-15

F1 · derivative.exercise_date: This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

SEC source: 0001636282-25-000002 · wk-form4_1736892981.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,379

F1 · kind: Represents the pro-rata distribution of shares of common stock for no consideration from a limited liability company in which the Reporting Person is a member.

SEC source: 0001636282-24-000089 · wk-form4_1731102826.xml · nonDerivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Sessions LLC

Disclosed balance after: 27,360

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2024.

F2 · balance_after: The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $36.48 to $37.00, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001636282-24-000070 · wk-form4_1730148059.xml · nonDerivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · By Sessions LLC

Disclosed balance after: 34,060

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2024.

SEC source: 0001636282-24-000068 · wk-form4_1727822060.xml · derivative · entry 1

Sloan Sheldon · CIK 0002038798 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2034-10-01

F1 · derivative.exercise_date: This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001636282-24-000062 · wk-form4_1725566647.xml · nonDerivative · entry 1

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,422

F1 · shares: The transaction reported reflects the sale of shares of common stock, par value $0.0001 per share, of the Issuer ("Common Stock") in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,739 restricted stock units ("RSUs"). This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade made by the Reporting Person.

F2 · price: The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $27.72 to $28.18, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Includes 101,214 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in three equal installments on each of September 1, 2025, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0000950170-24-061084 · ownership.xml · derivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Tomas Kiselak

Disclosed balance after: 11,323

Underlying: Common Stock · 11,323 shares

Expires 2034-05-14

F3 · derivative.exercise_date: This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to Tomas Kiselak's continuous service with the Issuer at each vesting date.

F4 · ownership.nature: Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0000950170-24-061084 · ownership.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Peter Harwin

Disclosed balance after: 11,323

Underlying: Common Stock · 11,323 shares

Expires 2034-05-14

F1 · derivative.exercise_date: This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to Peter Harwin's continuous service with the Issuer at each vesting date.

F2 · ownership.nature: Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Harwin holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0000950170-24-061083 · ownership.xml · derivative · entry 1

Milligan Sandra · CIK 0001859810 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,980

Underlying: Common Stock · 21,980 shares

Expires 2034-05-14

F1 · derivative.exercise_date: This option represents a right to purchase 21,980 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0000950170-24-061082 · ownership.xml · derivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,323

Underlying: Common Stock · 11,323 shares

Expires 2034-05-14

F1 · derivative.exercise_date: This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0000950170-24-061085 · ownership.xml · derivative · entry 1

Stelzer Laurie · CIK 0001644348 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,323

Underlying: Common Stock · 11,323 shares

Expires 2034-05-14

F1 · derivative.exercise_date: This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0000950170-24-061080 · ownership.xml · derivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,323

Underlying: Common Stock · 11,323 shares

Expires 2034-05-14

F1 · derivative.exercise_date: This option represents a right to purchase 11,323 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 14, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0000950170-24-048457 · ownership.xml · derivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 346,045

Underlying: Common Stock · 3,639,680 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F1 · kind: Pursuant to an Exchange Agreement between Fairmount Healthcare Fund II L.P. ("Fund II") and the Issuer dated as of April 23, 2024, Fund II exchanged 90,992 shares of Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") for 3,639,680 shares of Common Stock, effective on April 25, 2024.

F3 · derivative.exercise_date: Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F3 · derivative.expiration_date: Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-24-048457 · ownership.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 4,018,101

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to an Exchange Agreement between Fairmount Healthcare Fund II L.P. ("Fund II") and the Issuer dated as of April 23, 2024, Fund II exchanged 90,992 shares of Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") for 3,639,680 shares of Common Stock, effective on April 25, 2024.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-24-017494 · ownership.xml · nonDerivative · entry 1

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 746,907

F1 · kind: These shares were acquired under the Issuer's 2016 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F2 · balance_after: Includes 493,558 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0000950170-24-010901 · ownership.xml · derivative · entry 1

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2034-02-01

F1 · derivative.exercise_date: This option a right to purchase 70,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

SEC source: 0000950170-24-010904 · ownership.xml · derivative · entry 1

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,750

Underlying: Common Stock · 277,750 shares

Expires 2034-02-01

F1 · derivative.exercise_date: This option represents a right to purchase 277,750 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

SEC source: 0000950170-24-010896 · ownership.xml · derivative · entry 1

King-Jones Heidy · CIK 0001794898 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,000

Underlying: Common Stock · 63,000 shares

Expires 2034-02-01

F1 · derivative.exercise_date: This option represents a right to purchase 63,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

SEC source: 0000950170-24-011369 · ownership.xml · derivative · entry 1

McKenna Mark C. · CIK 0001749623 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-02-01

F1 · derivative.exercise_date: This option represents a right to purchase 40,000 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments beginning on February 1, 2024 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0000950170-23-073904 · ownership.xml · nonDerivative · entry 3

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · By Peter Harwin

Disclosed balance after: 406,038

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023.

SEC source: 0000950170-23-073904 · ownership.xml · nonDerivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · By Tomas Kiselak

Disclosed balance after: 406,038

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023.

SEC source: 0000950170-23-073904 · ownership.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · By Fairmount Healthcare Co-Invest L.P.

Disclosed balance after: 0

F1 · kind: Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount Healthcare Co-Invest L.P. ("Co-Invest") to its limited partners pursuant to a Rule 10b5-1 trading plan adopted by Co-Invest on September 29, 2023.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P. ("Fund I"), Fairmount Healthcare Fund II L.P. ("Fund II") and Co-Invest. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-23-072763 · ownership.xml · nonDerivative · entry 1

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,953

F1 · shares: Represents 134,953 restricted stock units ("RSUs") granted under the Spyre Therapeutics, Inc. 2016 Equity Incentive Plan, as Amended and Restated. Each RSU represents a contingent right to receive, upon vesting, one share of common stock, par value $0.0001 per share, of the Issuer. The RSUs vest as to one-fourth on each anniversary of September 1, 2023, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0000950170-23-069455 · ownership.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 16,667

Underlying: Common Stock · 666,680 shares

Expires not disclosed

F1 · derivative.exercise_price: Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F2 · shares: The shares of Series B Preferred Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended.

F1 · derivative.exercise_date: Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F1 · derivative.expiration_date: Following stockholder approval of the conversion of the Series B non-voting convertible preferred stock (the "Series B Preferred Stock") into shares of Common Stock, each share of Series B Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 0.00% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

F3 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-23-066131 · ownership.xml · derivative · entry 3

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 723,440 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations.

F1 · kind: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations.

F1 · derivative.exercise_date: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations.

F1 · derivative.expiration_date: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations.

SEC source: 0000950170-23-066131 · ownership.xml · nonDerivative · entry 1

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 746,507

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations.

F2 · shares: Includes 506,440 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.

F3 · balance_after: Includes 522,588 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0000950170-23-066399 · ownership.xml · derivative · entry 4

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Co-Invest L.P.

Disclosed balance after: 0

Underlying: Common Stock · 3,435,480 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.

F1 · derivative.exercise_date: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.

F1 · derivative.expiration_date: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-23-066399 · ownership.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund L.P. · CIK 0001686157 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest L.P. · CIK 0001982220 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Co-Invest L.P.

Disclosed balance after: 3,435,480

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain beneficial ownership limitations.

F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund L.P., Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest L.P. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000950170-23-069048 · ownership.xml · derivative · entry 3

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sessions LLC

Disclosed balance after: 0

Underlying: Common Stock · 34,360 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock automatically converted on November 24, 2023 into 40 shares of Common Stock, subject to certain limitations.

F1 · kind: Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock automatically converted on November 24, 2023 into 40 shares of Common Stock, subject to certain limitations.

F1 · derivative.exercise_date: Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock automatically converted on November 24, 2023 into 40 shares of Common Stock, subject to certain limitations.

F1 · derivative.expiration_date: Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock automatically converted on November 24, 2023 into 40 shares of Common Stock, subject to certain limitations.

SEC source: 0000950170-23-069048 · ownership.xml · nonDerivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sessions LLC

Disclosed balance after: 34,360

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock automatically converted on November 24, 2023 into 40 shares of Common Stock, subject to certain limitations.

SEC source: 0000950170-23-066146 · ownership.xml · derivative · entry 1

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-11-22

F1 · derivative.exercise_date: This option represents a right to purchase 50,000 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0000950170-23-066143 · ownership.xml · derivative · entry 1

Stelzer Laurie · CIK 0001644348 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-11-22

F1 · derivative.exercise_date: This option represents a right to purchase 50,000 shares of the Issuer's common stock, which will vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0000950170-23-066131 · ownership.xml · derivative · entry 2

Turtle Cameron · CIK 0001758363 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 374,000

Underlying: Common Stock · 374,000 shares

Expires 2033-11-22

F4 · derivative.exercise_date: This option represents a right to purchase 374,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on November 22, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.

SEC source: 0000950170-23-069048 · ownership.xml · derivative · entry 2

Albers Jeffrey W. · CIK 0001638474 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-11-22

F2 · derivative.exercise_date: This option represents a right to purchase 50,000 shares of the Issuer's Common Stock, which will vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

SEC source: 0000950170-23-046384 · ownership.xml · derivative · entry 1

Burrows Scott L · CIK 0001853327 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,121,441

Underlying: Common Stock · 10,121,441 shares

Expires 2033-09-01

F1 · derivative.exercise_date: This option represents a right to purchase 10,121,441 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0000950170-23-046396 · ownership.xml · derivative · entry 1

King-Jones Heidy · CIK 0001794898 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,495,255

Underlying: Common Stock · 13,495,255 shares

Expires 2033-09-01

F1 · derivative.exercise_date: This option represents the right to purchase 13,495,255 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

SEC source: 0001209191-23-040333 · doc4.xml · derivative · entry 1

Magovcevic-Liebisch Ivana · CIK 0001279281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,950,000

Underlying: Common Stock · 1,950,000 shares

Expires 2033-06-22

F1 · date: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001209191-23-040335 · doc4.xml · derivative · entry 1

Cox Russell J. · CIK 0001512984 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,950,000

Underlying: Common Stock · 1,950,000 shares

Expires 2033-06-22

F1 · date: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001209191-23-040328 · doc4.xml · derivative · entry 1

Lawton Alison Frances · CIK 0001542650 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,950,000

Underlying: Common Stock · 1,950,000 shares

Expires 2033-06-22

F1 · date: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001209191-23-040338 · doc4.xml · derivative · entry 1

Alspaugh Jonathan · CIK 0001868112 · President and CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,787,969

Underlying: Common Stock · 19,787,969 shares

Expires 2033-06-22

F1 · date: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on July 22, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-23-040329 · doc4.xml · derivative · entry 1

Smith Hunter C · CIK 0001636385 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,950,000

Underlying: Common Stock · 1,950,000 shares

Expires 2033-06-22

F1 · date: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.

SEC source: 0001209191-23-012882 · doc4.xml · derivative · entry 1

Neuman Linda L · CIK 0001951205 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550,000

Underlying: Common Stock · 550,000 shares

Expires 2033-02-22

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-23-012881 · doc4.xml · derivative · entry 1

Kastenmayer James Paul · CIK 0001798800 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2033-02-22

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-23-012877 · doc4.xml · derivative · entry 1

Hanley Jr. Michael Conick · CIK 0001791413 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2033-02-22

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 23, 2023, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.